Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.

Soung J, Cui Y, Bissonnette R, Lebwohl MG, González-Cantero Á, Pinter A, Rich P, Prajapati VH, Miller-Kassamali M, Cafone J, Jiang J, Li S, Yang YW, Pink AE

Open source

DOI
10.1016/j.jaad.2026.05.048
Published
2026 Oct
Container
Journal of the American Academy of Dermatology
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jaad.2026.05.048,
  title = {Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.},
  author = {Soung J and Cui Y and Bissonnette R and Lebwohl MG and González-Cantero Á and Pinter A and Rich P and Prajapati VH and Miller-Kassamali M and Cafone J and Jiang J and Li S and Yang YW and Pink AE},
  year = {2026},
  journal = {Journal of the American Academy of Dermatology},
  doi = {10.1016/j.jaad.2026.05.048},
  url = {https://doi.org/10.1016/j.jaad.2026.05.048}
}

RIS

TY  - JOUR
TI  - Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.
AU  - Soung J
AU  - Cui Y
AU  - Bissonnette R
AU  - Lebwohl MG
AU  - González-Cantero Á
AU  - Pinter A
AU  - Rich P
AU  - Prajapati VH
AU  - Miller-Kassamali M
AU  - Cafone J
AU  - Jiang J
AU  - Li S
AU  - Yang YW
AU  - Pink AE
PY  - 2026
JO  - Journal of the American Academy of Dermatology
DO  - 10.1016/j.jaad.2026.05.048
UR  - https://doi.org/10.1016/j.jaad.2026.05.048
ER  - 

APA

J, S., Y, C., R, B., MG, L., Á, G., A, P., P, R., VH, P., M, M., J, C., J, J., S, L., YW, Y., & AE, P. (2026). Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: Randomized treatment withdrawal in adults from the phase 3, ICONIC-LEAD study.. Journal of the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2026.05.048

Source records